Compare Vaxcyte Inc. Common Stock (PCVX) vs Verisign, Inc. (VRSN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vaxcyte Inc. Common Stock vs Verisign, Inc. — how do they compare? Vaxcyte Inc. Common Stock trades at $67.37 (market cap $10.51B), while Verisign, Inc. trades at $302.35 (market cap $27.28B). The key difference: Verisign, Inc. is far larger — about 2.6× Vaxcyte Inc. Common Stock's market cap, and Verisign, Inc. pays a 1.07% dividend while Vaxcyte Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Vaxcyte Inc. Common Stock for 0 Days and Verisign, Inc. for 124 Days on average.
| PCVX | VRSN | |
|---|---|---|
Market Cap | $10.51B | $27.28B |
Volume | 2,644,694 | 695,583 |
Sector | Health | Technology |
52-Week High | $73.82 | $310.00 |
52-Week Low | $40.32 | $211.49 |
Typical Hold Time | 0 Days | 124 Days |
Enterprise Value | $9.14B | $28.59B |
Dividend Yield | — | 1.07% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
VeriSign (VRSN) trades at $301.41, down 0.43% on the day, with a bullish technical outlook supported by moving averages and a consensus analyst price target of $348. The stock shows strong profitability with a net income margin near 50% and consistent revenue growth, though recent quarterly EPS results have been mixed. Key developments include an upcoming Q3 2026 earnings report and ongoing institutional accumulation, balanced by an antitrust lawsuit and insider selling activity.
The outlook for VRSN remains positive given its dominant market position and high margins, with potential upside to analyst targets. Risks include legal challenges, competitive pressures, and valuation multiples above industry averages. Earnings performance and resolution of regulatory issues will be critical near-term catalysts for the stock.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Vaxcyte Inc. Common Stock
Vaxcyte, Inc. is a clinical-stage vaccine company that engineers protein-based vaccines to prevent bacterial diseases such as invasive pneumococcal disease, using its proprietary cell-free protein synthesis platform to develop candidates including the pneumococcal conjugate vaccines VAX-31 and VAX-24.
Read more on PCVX →About Verisign, Inc.
Verisign is the sole authorized registry for several generic top-level domains, including the widely utilized .com and .net top-level domains. The company operates critical Internet infrastructure to support the domain name system, including operating two of the world's 13 root servers that are used to route Internet traffic. In 2018, the firm sold off its Security Services business, signalling a renewed focus on the core registry business.
Read more on VRSN →
